Skip to content

Robot-assisted Versus Laparoscopic Surgery for Left-sided Colon Cancer: A Multicenter Randomized Controlled Trial

Robot-assisted Versus Laparoscopic Surgery for Left-sided Colon Cancer: A Multicenter Randomized Controlled Trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900023919
Enrollment
Unknown
Registered
2019-06-18
Start date
2020-01-01
Completion date
Unknown
Last updated
2019-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Let-sided colon cancer

Interventions

Sponsors

the First Affiliated Hospital of Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Aged 18 to 80 years; (2) The tumor is located in the left-sided colon: left 1/3 of transverse colon,spleen curvature of colon, decending colon; (3) Pathologic biopsy confirmed the left-sided colon adenocarcinoma; (4) Preoperative clinical stage: locally advanced left-sided colon adenocarcinoma(cT2-4,N0-2,M0AJCC-8); (5) R0 results are expected from left hemicolectomy and regional lymph node dissection; (6) Preoperative ECOG physical state score: 0/1; (7) Preoperative ASA score: I-III; (8) Patient or family members understand the research program and are willing to participate in this study and sign written informed consent.

Exclusion criteria

Exclusion criteria: 1. Severe mental illness; 2. Emergency surgery for acute intestinal obstruction, bleeding and perforation in the left-sided colon adenocarcinoma; 3. Multiple primary colorectal malignant tumors; 4. Family adenomatosis (FAP), Lynch syndrome, inflammatory bowel disease; 5. Patients with left-sided colon adenocarcinoma who have undergone new adjuvant therapy before surgery; 6. History of abdominal surgery; 7. Pregnant or lactating women; 8. There were other malignant diseases within 5 years; 9. There were simultaneous surgical treatment for other diseases; 10. There were continuous systemic corticosteroid therapy within 1 month; 11. There were unstable angina or myocardial infarction within 6 months; 12. There were cerebral infarction or cerebral hemorrhage within 6 months; 13. Pulmonary function test FEV1< 50%.

Design outcomes

Primary

MeasureTime frame
3-year disease-free survival;postoperative complication rate;

Secondary

MeasureTime frame
3-year overall survival; 5-year disease-free and overall survival;3/5-year locoregional recurrence rate;operative duration;conversion to open surgery;Postoperative recovery time;postoperative 30-day mortality rate;

Countries

China

Contacts

Public ContactTaiyuan Li

the First Affiliated Hospital of Nanchang University

jylitaiyuan@sina.com+86 0791-88694893

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026